Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2024-05-17 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司股东询价转让计划书
Share Issue/Capital Change Classification · 95% confidence The document is titled as a "股东询价转让计划书" which translates to "Shareholder Inquiry Transfer Plan". It details a non-public transfer of shares by existing shareholders before the company's IPO, including the number of shares, shareholders involved, transfer price determination, and conditions for investors. The document is an announcement regarding a share transfer plan and does not contain financial statements, earnings data, or management discussion. It is not a report but an announcement of a capital transaction involving share transfers. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as share transfers by shareholders.
2024-05-17 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司股东向特定机构投资者询价转让股份相关资格的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the qualification verification of shareholders involved in a specific share transfer transaction to designated institutional investors. It references regulatory rules related to share transfer and shareholder qualifications, and provides verification opinions from a financial institution (China International Capital Corporation). The document does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. It is a regulatory announcement about a capital transaction process, specifically a share transfer inquiry and qualification check. This fits best under Capital/Financing Update (CAP) as it relates to share transfer and capital structure changes.
2024-05-17 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司首次公开发行股票并在科创板上市的保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "保荐总结报告书" which translates to "Sponsorship Summary Report" related to the initial public offering (IPO) and listing of Chengdu Lead Drug Development Co., Ltd. on the STAR Market. It is issued by China International Capital Corporation Limited as the sponsor. The content includes details about the IPO approval, the sponsor's duties during the IPO and continuous supervision period, changes in sponsorship representatives, and compliance with regulatory requirements. It does not contain financial statements or quarterly/yearly financial results but rather a summary and compliance report related to the IPO sponsorship and ongoing supervision. This type of document is a specialized report related to capital market activities, specifically the sponsorship and supervision of an IPO, which aligns best with the category of Capital/Financing Update (CAP). The document length is 4057 characters, which is substantive and not a mere announcement or certification. Therefore, the most appropriate classification is CAP with high confidence.
2024-05-09 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2023年度持续督导跟踪报告
Management Reports Classification · 95% confidence The document is titled as a "2023 Annual Continuous Supervision Tracking Report" issued by a sponsoring institution for a listed company, referencing regulatory rules from the China Securities Regulatory Commission and Shanghai Stock Exchange. It contains detailed descriptions of ongoing supervision activities, risk factors, financial data for the year 2023, and operational updates. The content includes comprehensive financial figures, management discussion of business risks, and operational highlights for the full fiscal year 2023. This aligns with a detailed management report or supervisory report rather than a simple announcement or certification. The document length is substantial (15,000 characters), and it contains substantive financial and operational data, not just an announcement or certification. It is not a full annual report (10-K) but rather a continuous supervision tracking report by the sponsor, which is a type of management report explaining company operations, risks, and financial performance. Therefore, the best fitting category is Management Reports (MDA).
2024-05-09 Chinese
成都先导药物开发股份有限公司关于公司监事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor (监事) from the supervisory board of 成都先导药物开发股份有限公司. It details the resignation reason, the impact on the supervisory board, and the company's plan to fill the vacancy. There is no financial data, no mention of annual or quarterly reports, no voting results, no legal proceedings, or other report types. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-05-06 Chinese
成都先导药物开发股份有限公司2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) Meeting Materials". It contains detailed information about the AGM including meeting agenda, voting procedures, and multiple proposals to be discussed and voted on during the AGM. The document includes agenda items such as the 2023 annual report, financial statements, profit distribution plan, 2024 financial budget, director and supervisor remuneration plans, and board and supervisory reports. The content is consistent with materials typically prepared and distributed for an Annual General Meeting to inform shareholders and facilitate discussion and voting. There is no indication that this is the actual annual report or financial statements themselves, but rather the meeting materials for the AGM. The document length is substantial (15,000 characters), and it is not a brief announcement or a certification. Therefore, the document fits the category of AGM Information (AGM-R).
2024-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.